Silvana N. C.
- Country
- Spain
- Department
- Department of Hematology
Research Overview
- Evaluation of Odronextamab's Anti-Tumor Efficacy and Safety in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Patients
- Efficacy and Safety Evaluation of Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia: A Phase 3 Randomized Study
- Efficacy and Safety Evaluation of Efgartigimod Alfa in Adults with Primary Immune Thrombocytopenia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 22 of 98 partner sites.
Specializations
Hematological Disorders
The investigator specializes in treating primary immune thrombocytopenia (ITP), conducting research with novel therapeutic agents to improve disease control in adult patients.
- Immune-mediated platelet disorders
- Chronic and persistent ITP management
- Novel immunomodulatory therapies
Their work includes evaluation of innovative treatments such as efgartigimod and rilzabrutinib for refractory cases.
Lymphoid Malignancies
The investigator focuses on treating various forms of B-cell non-Hodgkin lymphoma (B-NHL), particularly in cases resistant to conventional therapies.
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
Their research involves novel targeted therapies including odronextamab for patients with relapsed or refractory disease.
Advanced Therapeutics
The investigator explores innovative treatment approaches for patients who have exhausted standard therapeutic options.
- Immunotherapy development
- Targeted biological agents
- Treatment-resistant conditions
Their work encompasses both autoimmune disorders and hematologic malignancies, with particular attention to novel therapeutic mechanisms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.